Sold as Parathar. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Teriparatide Acetate (sold as Parathar), with 0 new uses approved and 0 published complete response letters.
| A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing RegimensPostmenopausal Women With Osteoporosis · Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 2 | Recruiting | May 12, 2026 |
| A Study of B-3E07 and Forsteo® in Healthy Adult Female ParticipantsHealthy Volunteers · Syneos Health | Phase 1 | Recruiting | Mar 27, 2026 |
| Chronotherapeutic Optimization of Teriparatide Administration in Postmenopausal OsteoporosisCircadian Rhythm Disorders, Osteoporosis · Peking University Third Hospital | Not applicable | Not yet recruiting | Apr 30, 2025 |
| To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of FracturePostmenopausal Women With Osteoporosis · Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Mar 27, 2025 |
| Relationship Between Thoracic Hyperkyphosis and Fall Risk in Women with Fragility Vertebral FracturesOsteoporosis, Hyperkyphosis · University of Palermo | — | Active, not recruiting | Feb 24, 2025 |
| Combined Anabolic TherapyOsteoporosis, Postmenopausal, Osteoporosis · Massachusetts General Hospital | Phase 4 | Recruiting | Aug 16, 2024 |
| PROactive HEALing in High-Risk Pelvic and Non-hip Lower Extremity Fragility Fractures (PRO HEAL Pilot)Lower Extremity Fractures, Pelvis · University of Calgary | Phase 1 / Phase 2 | Not yet recruiting | Mar 12, 2024 |
| Precision Medicine Approach for Osteoporosis - Follow Up StudyOsteoporosis · Paul F Netzel | Phase 4 | Enrolling by invitation | Feb 20, 2024 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| — | ParatharNDA 19498 | Sanofi Aventis US | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Sanofi Aventis US